In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Sanofi is the third company - along with J&J and Eli Lilly - to attempt to change the way it pays for medicines under the ...

The drugmaker looks to rein in how it gives discounts in a federal program designed to help hospitals that serve low-income ...

In a letter sent to hospitals and clinics on Friday, Sanofi indicated that certain hospitals covered by the 340B Drug ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.

Sanofi is proposing a new model for distributing drug discounts under the federal 340B program, according to the Wall Street ...

Sanofi (SNY) is planning changes to its 340B plan on how it gives discounts to certain hospitals, planning to require institutions to provide ...

The federal government created this system in 1992 as part of the 340B program to reduce drug prices. Sanofi’s new plan will allegedly require hospitals to show the details of their pharmacy and ...

Sanofi plans to phase in its model for different 340B-eligible providers starting early next year. The rebates would apply to 25 drugs, including Dupixent, an injectable used to treat inflammatory ...

French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...